Adrenocorticotrophic Hormone
Phase 3Small molecule
Adrenocorticotrophic Hormone is one of 26 small molecule programs targeting Cortisol. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
30 competitors in Nephrotic Syndrome
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Cellcept
RocheApproved
Farxiga
AstraZenecaApproved
Neoral
NovartisApproved
Lovenox
SanofiApproved
Rayos
RRoxane Laboratories
Approved
Aldactone
PfizerApproved
Thalitone
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Ottawa